Sign up here for our daily coronavirus newsletter on what you need to know, andsubscribe to our Covid-19 podcast for the latest news and analysis.
Novartis AG will run a U.S. study of the malaria drug hydroxychloroquine for Covid-19, the latest effort to determine whether the hyped medicine can help in the battle against the pandemic.
The 65-year-old medicine will be tested against a placebo alone and in combination with the antibiotic azithromycin in a study of about 440 hospitalized patients, the Swiss drugmakersaid Monday. Novartis hopes to have results as soon as early summer.
With no drugs proven to defeat the new coronavirus, doctors are using medicines developed for other ailments and reporting some successes that then need to be verified or debunked in clinical trials.
26,889 in U.S.Most new cases today
-16% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23
-1.104 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23